On May 12, 2026, Outlook Therapeutics, Inc. entered a sales agreement with H.C. Wainwright to offer up to $100 million of its common stock. The company reported approximately $7.7 million in cash as of March 31, 2026, excluding $4.5 million from a prior equity offering.